Medicine and Dentistry
Prostate Cancer
100%
Metastatic Carcinoma
30%
Neoplasm
28%
Prostatectomy
28%
Surgery
19%
Biopsy Technique
17%
Prostate Specific Antigen
17%
Apalutamide
16%
Phase II Trials
16%
Partial Nephrectomy
16%
Kidney Metastasis
16%
Castration Resistant Prostate Cancer
16%
Diseases
14%
Nephrectomy
9%
Biochemical Recurrence
9%
Androgen Receptor
8%
Pelvis
8%
Single Nucleotide Polymorphism
8%
Quality Improvement
8%
Nonsteroid Antiinflammatory Agent
8%
Panniculectomy
8%
Antigen
8%
Apixaban
8%
Dormancy
8%
Nephropathy
8%
Cancer Cell
8%
Dyslipidemia
8%
Metabolic Syndrome
8%
Sarcopenia
8%
Anthropometry
8%
Nephroureterectomy
8%
Drug Use
8%
Phallus
8%
Acetylsalicylic Acid
8%
Immunotherapy
8%
Oncology
8%
Cell Heterogeneity
8%
Renal Failure
8%
Axitinib
8%
Cancer Recurrence
8%
Glomerular Filtration Rate
8%
Visceral Pleura
8%
Neoadjuvant Chemotherapy
8%
Chromogranin A
8%
Transitional Cell Carcinoma
8%
Thromboembolism
8%
Body Mass Index
8%
Targeted Therapy
8%
Synaptophysin
8%
Robot-Assisted Prostatectomy
8%
Keyphrases
Radical Prostatectomy
28%
Prostate Cancer
22%
Phase II Trial
21%
Molecular Predictors
16%
Metastatic Renal Cell Carcinoma (mRCC)
16%
Intermediate-risk Prostate Cancer
16%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
16%
Apalutamide
16%
Metastatic Disease
15%
Surgical Management
12%
High Risk
10%
High-risk Disease
10%
Prostate Cancer Patients
10%
Prostate Cancer Cells
9%
Metastasis
9%
Tumor
9%
Androgen Receptor
8%
Breast Cancer
8%
Confidence Interval
8%
Approaches to Management
8%
Neoadjuvant Chemotherapy
8%
Suspected Prostate Cancer
8%
Aspirin
8%
Upper Tract Urothelial Carcinoma
8%
Neoadjuvant
8%
Disseminated Tumor Cells
8%
Locally Advanced
8%
Chromogranin A
8%
Anthropometric Parameters
8%
Biochemical Recurrence
8%
Hypoxia
8%
TMPRSS2-ERG Fusion
8%
Prostate Cancer Recurrence
8%
Adherent Perinephric Fat
8%
Tumor Aggression
8%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8%
Primary Surgery
8%
Risk Factors for Complications
8%
Dormancy
8%
Cancer-related
8%
Pleura
8%
Circulating microRNA
8%
Metabolic Syndrome
8%
Renal Insufficiency
8%
Axitinib
8%
Locally Advanced Prostate Cancer
8%
Partial Nephrectomy
8%
Drug Use
8%
Castration-resistant Prostate Cancer
8%
Glomerular Filtration Rate
8%
